The National Pharmaceutical Pricing Authority (NPPA) has fixed ceiling prices of over 870 formulations that are part of the National List of Essential Medicines (NLEM) through an order on March 30, allowing a 10.76 per cent rise linked to the Wholesale Price Index (WPI). This is the highest price rise allowed for scheduled drugs (those part of the NLEM) by the pricing regulator since the Drug Price Control Order, 2013, came into effect. The average increase in prices was 3.1 per cent in the past five years.
An analysis by Systematix Research showed that among the three components of growth for